![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Tesaro’s Niraparib Soars in Phase 3 Study
Tesaro’s Niraparib Soars in Phase 3 Study
Tesaro’s niraparib scored in a Phase 3 trial evaluating the treatment in patients suffering from ovarian cancer, meeting its primary endpoint of progression-free survival.
In both cohorts of the study, the candidate significantly extended progression-free survival compared to the control.
Currently, there is no FDA-approved drug for maintenance treatment of patients with recurrent ovarian cancer following a reaction to platinum-based treatments, according to the company.
Upcoming Events
-
21Oct